|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MTF2 |
Gene summary for MTF2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MTF2 | Gene ID | 22823 |
| Gene name | metal response element binding transcription factor 2 | |
| Gene Alias | M96 | |
| Cytomap | 1p22.1 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | B4DZ69 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 22823 | MTF2 | CCI_2 | Human | Cervix | CC | 9.33e-06 | 7.56e-01 | 0.5249 |
| 22823 | MTF2 | CCI_3 | Human | Cervix | CC | 5.88e-09 | 8.29e-01 | 0.516 |
| 22823 | MTF2 | LZE4T | Human | Esophagus | ESCC | 1.90e-09 | 2.43e-01 | 0.0811 |
| 22823 | MTF2 | LZE7T | Human | Esophagus | ESCC | 7.76e-13 | 6.88e-01 | 0.0667 |
| 22823 | MTF2 | LZE8T | Human | Esophagus | ESCC | 1.63e-12 | 3.23e-01 | 0.067 |
| 22823 | MTF2 | LZE20T | Human | Esophagus | ESCC | 9.83e-15 | 2.79e-01 | 0.0662 |
| 22823 | MTF2 | LZE24T | Human | Esophagus | ESCC | 5.00e-13 | 2.44e-01 | 0.0596 |
| 22823 | MTF2 | LZE21T | Human | Esophagus | ESCC | 8.49e-03 | 2.55e-01 | 0.0655 |
| 22823 | MTF2 | LZE6T | Human | Esophagus | ESCC | 2.34e-03 | 1.71e-01 | 0.0845 |
| 22823 | MTF2 | P1T-E | Human | Esophagus | ESCC | 1.42e-14 | 5.03e-01 | 0.0875 |
| 22823 | MTF2 | P2T-E | Human | Esophagus | ESCC | 1.39e-44 | 7.91e-01 | 0.1177 |
| 22823 | MTF2 | P4T-E | Human | Esophagus | ESCC | 5.22e-22 | 3.87e-01 | 0.1323 |
| 22823 | MTF2 | P5T-E | Human | Esophagus | ESCC | 3.30e-20 | 4.22e-01 | 0.1327 |
| 22823 | MTF2 | P8T-E | Human | Esophagus | ESCC | 2.41e-23 | 4.73e-01 | 0.0889 |
| 22823 | MTF2 | P9T-E | Human | Esophagus | ESCC | 5.13e-15 | 2.16e-01 | 0.1131 |
| 22823 | MTF2 | P10T-E | Human | Esophagus | ESCC | 1.09e-42 | 7.48e-01 | 0.116 |
| 22823 | MTF2 | P11T-E | Human | Esophagus | ESCC | 6.60e-05 | 2.52e-01 | 0.1426 |
| 22823 | MTF2 | P12T-E | Human | Esophagus | ESCC | 1.62e-84 | 1.80e+00 | 0.1122 |
| 22823 | MTF2 | P15T-E | Human | Esophagus | ESCC | 1.44e-26 | 5.43e-01 | 0.1149 |
| 22823 | MTF2 | P16T-E | Human | Esophagus | ESCC | 4.75e-11 | 2.90e-01 | 0.1153 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00488634 | Cervix | CC | stem cell differentiation | 46/2311 | 206/18723 | 4.11e-05 | 6.36e-04 | 46 |
| GO:00063257 | Cervix | CC | chromatin organization | 78/2311 | 409/18723 | 5.40e-05 | 8.02e-04 | 78 |
| GO:00165705 | Cervix | CC | histone modification | 84/2311 | 463/18723 | 1.70e-04 | 2.01e-03 | 84 |
| GO:00349685 | Cervix | CC | histone lysine methylation | 27/2311 | 115/18723 | 6.61e-04 | 6.09e-03 | 27 |
| GO:00310565 | Cervix | CC | regulation of histone modification | 33/2311 | 152/18723 | 7.97e-04 | 7.00e-03 | 33 |
| GO:00987275 | Cervix | CC | maintenance of cell number | 30/2311 | 134/18723 | 7.98e-04 | 7.00e-03 | 30 |
| GO:00198274 | Cervix | CC | stem cell population maintenance | 29/2311 | 131/18723 | 1.17e-03 | 9.47e-03 | 29 |
| GO:00165715 | Cervix | CC | histone methylation | 30/2311 | 141/18723 | 1.88e-03 | 1.39e-02 | 30 |
| GO:19908234 | Cervix | CC | response to leukemia inhibitory factor | 22/2311 | 95/18723 | 2.40e-03 | 1.70e-02 | 22 |
| GO:00180224 | Cervix | CC | peptidyl-lysine methylation | 28/2311 | 131/18723 | 2.43e-03 | 1.71e-02 | 28 |
| GO:00064795 | Cervix | CC | protein methylation | 36/2311 | 181/18723 | 2.46e-03 | 1.71e-02 | 36 |
| GO:00082135 | Cervix | CC | protein alkylation | 36/2311 | 181/18723 | 2.46e-03 | 1.71e-02 | 36 |
| GO:19908304 | Cervix | CC | cellular response to leukemia inhibitory factor | 21/2311 | 94/18723 | 4.68e-03 | 2.82e-02 | 21 |
| GO:00182054 | Cervix | CC | peptidyl-lysine modification | 62/2311 | 376/18723 | 1.04e-02 | 4.97e-02 | 62 |
| GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
| GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
| GO:00434143 | Esophagus | ESCC | macromolecule methylation | 199/8552 | 316/18723 | 3.44e-10 | 9.57e-09 | 199 |
| GO:003105614 | Esophagus | ESCC | regulation of histone modification | 106/8552 | 152/18723 | 1.52e-09 | 3.55e-08 | 106 |
| GO:00322592 | Esophagus | ESCC | methylation | 222/8552 | 364/18723 | 2.26e-09 | 5.09e-08 | 222 |
| GO:000632517 | Esophagus | ESCC | chromatin organization | 240/8552 | 409/18723 | 6.52e-08 | 1.14e-06 | 240 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MTF2 | SNV | Missense_Mutation | c.1412N>G | p.Ser471Cys | p.S471C | Q9Y483 | protein_coding | deleterious(0) | possibly_damaging(0.794) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MTF2 | SNV | Missense_Mutation | c.1020G>C | p.Lys340Asn | p.K340N | Q9Y483 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AO-A0JM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| MTF2 | insertion | Frame_Shift_Ins | novel | c.1230_1231insTATATTTTATT | p.Arg411TyrfsTer7 | p.R411Yfs*7 | Q9Y483 | protein_coding | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| MTF2 | insertion | Frame_Shift_Ins | novel | c.1180_1181insTAAAAAAAGT | p.Glu394ValfsTer29 | p.E394Vfs*29 | Q9Y483 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | ||
| MTF2 | insertion | Frame_Shift_Ins | rs774769534 | c.1180_1181insA | p.Gly397ArgfsTer23 | p.G397Rfs*23 | Q9Y483 | protein_coding | TCGA-AR-A0U2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | PD | ||
| MTF2 | insertion | Nonsense_Mutation | novel | c.1719_1720insTCTTGGAGCTGAA | p.Arg574SerfsTer4 | p.R574Sfs*4 | Q9Y483 | protein_coding | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| MTF2 | insertion | Nonsense_Mutation | novel | c.1679_1680insAAAGGCAACCTTAAATTAATAGC | p.Arg561LysfsTer6 | p.R561Kfs*6 | Q9Y483 | protein_coding | TCGA-BH-A0E0-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| MTF2 | SNV | Missense_Mutation | novel | c.206T>C | p.Ile69Thr | p.I69T | Q9Y483 | protein_coding | deleterious(0) | probably_damaging(0.925) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MTF2 | SNV | Missense_Mutation | rs759180756 | c.1045C>T | p.Arg349Cys | p.R349C | Q9Y483 | protein_coding | deleterious(0.03) | possibly_damaging(0.769) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MTF2 | insertion | Frame_Shift_Ins | novel | c.186_187insA | p.Leu63ThrfsTer19 | p.L63Tfs*19 | Q9Y483 | protein_coding | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |